Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression

Gut

Volumn 61, Issue 6, 2012, Pages 855-864

  De Wit, Meike ^a   Jimenez, Connie R ^a   Carvalho, Beatriz ^a   Belien, Jeroen A M ^a   Delis van Diemen, Pien M ^a   Mongera, Sandra ^a   Piersma, Sander R ^a   Vikas, Maindad ^b   Navani, Sanjay ^b   Pontén, Fredrik ^c   Meijer, Gerrit A ^a   Fijneman, Remond J A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Lab Surgpath   (India)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE TRANSPORTER 1; MESSENGER RNA; PRION PROTEIN;

ARTICLE; BIOTINYLATION; CANCER CELL; CANCER GROWTH; CELL ISOLATION; CELL SURFACE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; FLUORINE NUCLEAR MAGNETIC RESONANCE; GEL ELECTROPHORESIS; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; NUCLEOTIDE SEQUENCE; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRNP GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SLC2A1 GENE; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY;

ADENOMA; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CACO-2 CELLS; CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLUCOSE TRANSPORTER TYPE 1; HT29 CELLS; HUMANS; NEOPLASM PROTEINS; PRIONS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; PRPC PROTEINS;

EID: 84860579793     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300511     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5. (Pubitemid 39429665)
3. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.
4. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059-72.
5. Carvalho B, Postma C, Mongera S, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009;58:79-89.
6. Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002;123:1109-19.
7. Shinya H, Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 1979;190:679-83.
8. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9. (Pubitemid 351483372)
9. van Dongen GA, Visser GW, Lub-de Hooge MN, et al. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007;12:1379-89.
10. Pan D, Lanza GM, Wickline SA, et al. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009;70:274-85.
11. Lowik CW, Kaijzel E, Que I, et al. Whole body optical imaging in small animals and its translation to the clinic: intra-operative optical imaging guided surgery. Eur J Cancer 2009;(45 Suppl 1):391-3.
12. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26:3661-78. (Pubitemid 46842711)
13. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
14. Albrethsen J, Knol JC, Piersma SR, et al. Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010;9:988-1005.
15. Jimenez CR, Knol JC, Meijer GA, et al. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010;73:1873-95.
16. Rajcevic U, Niclou SP, Jimenez CR. Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009;14:3292-303.
17. Conrotto P, Roesli C, Rybak J, et al. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008;123:2856-64.
18. Luque-Garcia JL, Martinez-Torrecuadrada JL, Epifano C, et al. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010;10:940-52.
19. Roesli C, Borgia B, Schliemann C, et al. Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res 2009;69:5406-14.
20. Scheurer SB, Rybak JN, Roesli C, et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005;5:2718-28. (Pubitemid 41059751)
21. Scheurer SB, Roesli C, Neri D, et al. A comparison of different biotinylation reagents, tryptic digestion procedures, and mass spectrometric techniques for 2-D peptide mapping of membrane proteins. Proteomics 2005;5:3035-9. (Pubitemid 41176468)
22. Piersma SR, Fiedler U, Span S, et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 2010;9:1913-22.
23. Nesvizhskii AI, Keller A, Kolker E, et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-58. (Pubitemid 37082259)
24. Keller A, Nesvizhskii AI, Kolker E, et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-92. (Pubitemid 35215372)
25. Brennan DJ, O'Connor DP, Rexhepaj E, et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 2010;10:605-17.
26. van de Wiel MA, Kim KI, Vosse SJ, et al. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007;23:892-4. (Pubitemid 47049924)
27. Buffart TE, Coffa J, Hermsen MA, et al. DNA copy number changes at 8q11-24 in metastasized colorectal cancer. Cell Oncol 2005;27:57-65. (Pubitemid 40387193)
28. Kall L, Krogh A, Sonnhammer EL. A combined transmembrane topology and signal peptide prediction method. J Mol Biol 2004;338:1027-36. (Pubitemid 38542831)
29. Breen E, Clarke A, Steele G Jr, et al. Poorly differentiated colon carcinoma cell lines deficient in alpha-catenin expression express high levels of surface E-cadherin but lack Ca(2+)-dependent cell-cell adhesion. Cell Adhes Commun 1993;1:239-50. (Pubitemid 2031275)
30. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-5.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
32. Greijer AE, Delis-van Diemen PM, Fijneman RJ, et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 2008;452:535-44.
33. Airley R, Evans A, Mobasheri A, et al. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 2010;192:133-8.
34. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61. (Pubitemid 351694453)
35. Witte D, Ali N, Carlson N, et al. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 2002;22:2555-7. (Pubitemid 36069279)
36. Mehrpour M, Codogno P. Prion protein: from physiology to cancer biology. Cancer Lett 2009;290:1-23.
37. Antonacopoulou AG, Palli M, Marousi S, et al. Prion protein expression and the M129V polymorphism of the PRNP gene in patients with colorectal cancer. Mol Carcinog 2010;49:693-9.
38. Du J, Pan Y, Shi Y, et al. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer 2005;113:213-20. (Pubitemid 39628311)
39. McEwan JF, Windsor ML, Cullis-Hill SD. Antibodies to prion protein inhibit human colon cancer cell growth. Tumour Biol 2009;30:141-7.
40. Wurm S, Wechselberger C. Prion protein modifies TGF-beta induced signal transduction. Biochem Biophys Res Commun 2006;349:525-32. (Pubitemid 44344553)
41. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008;7:592-6. (Pubitemid 351498996)
42. Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res 2009;151:163-70.
43. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165-80.
44. Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009;15:9-20.
45. Cai D, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009;9:102.
46. Eyler CE, Telen MJ. The Lutheran glycoprotein: a multifunctional adhesion receptor. Transfusion 2006;46:668-77.
47. Lin YC, Shun CT, Wu MS, et al. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006;12:7165-73.
48. Toiyama Y, Miki C, Inoue Y, et al. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol 2008;15:1617-24.
49. Brooks KJ, Coleman EJ, Vitetta ES. The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. Int J Cancer 2008;123:2438-45.
50. Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010;138:2151-62.
51. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-47.
52. van Kouwen MC, Nagengast FM, Jansen JB, et al. 2-(18F)-fluoro-2-deoxy- Dglucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 2005;23:3713-17.